All In Biotech

Drug Trial Radar · NCT01343277

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma

Last checked: Nov 19, 2026Latest source record: Aug 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 579 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

579

Actual

Start

Jun 2011

Primary completion

Jan 2015

Study completion Apr 2016

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
PharmaMar
First posted
Apr 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).

Conditions

  • Advanced Liposarcoma or Leiomyosarcoma

Interventions

  • TrabectedinDrug

    Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.

  • DacarbazineDrug

    Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015]

Locations

88 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Hartford, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Post Falls, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Springfield, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Sioux City, Iowa

  • Site not named

    Overland Park, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Covington, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Lansing, Michigan

  • Site not named

    Jackson, Mississippi

  • Site not named

    Saint Joseph, Missouri

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.